Epizyme Inc. (NASDAQ:EPZM)’s share price dropped 3.8% during trading on Tuesday . The company traded as low as $9.65 and last traded at $9.69, with a volume of 114,062 shares. The stock had previously closed at $10.07.

EPZM has been the topic of a number of recent research reports. Citigroup Inc. initiated coverage on Epizyme in a research note on Tuesday, April 5th. They set a “buy” rating and a $17.00 price objective on the stock. Leerink Swann restated a “buy” rating on shares of Epizyme in a research note on Tuesday, April 19th. Cowen and Company restated a “buy” rating on shares of Epizyme in a research note on Monday, June 20th. Mizuho restated a “buy” rating and set a $18.00 price objective on shares of Epizyme in a research note on Monday, June 20th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $26.00 price objective on shares of Epizyme in a research note on Monday, June 20th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $23.11.

The stock’s market cap is $555.63 million. The firm’s 50 day moving average is $10.92 and its 200-day moving average is $10.59.

Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, May 9th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.53) by $0.12. On average, analysts forecast that Epizyme Inc. will post ($2.25) earnings per share for the current year.

In related news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction that occurred on Tuesday, July 5th. The shares were sold at an average price of $10.03, for a total value of $40,120.00. Following the completion of the transaction, the insider now owns 4,000 shares in the company, valued at $40,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of hedge funds and institutional investors have recently modified their holdings of EPZM. Jennison Associates LLC increased its position in shares of Epizyme by 252.4% in the fourth quarter. Jennison Associates LLC now owns 893,913 shares of the biopharmaceutical company’s stock worth $14,320,000 after buying an additional 640,245 shares in the last quarter. California Public Employees Retirement System purchased a new position in shares of Epizyme during the fourth quarter worth about $2,723,000. Finally, Jennison Associates increased its position in shares of Epizyme by 0.6% in the third quarter. Jennison Associates now owns 253,668 shares of the biopharmaceutical company’s stock worth $3,262,000 after buying an additional 1,551 shares in the last quarter.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.